Analysis of the components and main ingredients of Icrituzumab

Epcoritumab (Epcoritamab) is an innovative bispecific antibody. Its core composition is based on the IgG1 antibody framework structure. It uses advanced antibody engineering technology to simultaneously recognize two different targets, namely CD3 (present on the surface of T cells) and CD20 (present on the surface of B cells). This structural design allows icarelatumumab to "bridge" T cells and malignant B cells in patients at the cellular level, allowing T cells in the immune system to be accurately "recruited" to the vicinity of tumor cells and activated to release cytotoxic molecules such as perforin and granzymes, thereby inducing tumor cell apoptosis.

From a molecular composition point of view, icorelatumumab is based on a fully humanizedIgG1 antibody molecule. It optimizes the Fc structure to extend the half-life and reduce unnecessary Fc-mediated toxic reactions. Its bispecific part is composed of two different variable fragments (scFv) fused, corresponding to the CD3 and CD20 sites respectively. This molecular design not only ensures high-affinity binding to tumor targets, but also enhances treatment selectivity and reduces "accidental injury" to non-target cells, thus improving efficacy while reducing systemic toxic and side effects.

In addition, the drug was developed using Genmab's patented antibody platform technology (such as DuoBody), which allows the precise integration of two target recognition capabilities in one antibody molecule. It not only has the advantages of high structural stability and uniform biodistribution, but also maintains the pharmacokinetic characteristics of traditional monoclonal antibodies. This structure allows icarelatumumab to be administered via subcutaneous injection, avoiding the inconvenience of intravenous injection and reducing the risk of cytokine release syndrome (CRS).

Taken together, the main component of icorelatumumab is a bispecific antibody based on an engineeredIgG1 skeleton structure, and its mechanism of action is based on precise immune activation. The design of the drug achieves a balance between immune recognition accuracy, cytotoxicity efficacy and treatment tolerance, which is one of the important advances in the current treatment strategy for B-cell malignant tumors.

Reference materials:https://www.drugs.com/epcoritamab.html